INTRODUCTION {#s1}
============

Acute lymphoblastic leukemia (ALL) is characterized by an excess of lymphoblasts of either the B- or T-lineage. If untreated the disease progresses rapidly and can be fatal within weeks to months. Adult patients with ALL who have had an allogeneic haematopoietic stem cell transplant (allo-HSCT) have an improved overall survival (OS) rate of 27--65% compared with 15--45% in the absence of allo-HSCT \[[@R1]--[@R3]\]. While the improvement in survival post-allogeneic HSCT may in part be due to the use of intensive chemotherapy and radiotherapy (such as total body irradiation) as conditioning, there does appear to be an increased survival advantage following HSCT using reduced intensity conditioning schedules in older patients and those with co-morbid risk factors \[[@R4], [@R5]\]. This suggests that post-transplant mechanisms, probably immunological in nature, play an important role in disease control with graft versus leukemia (GvL) effective in the eradication of residual disease. The 'GvL effect' has been demonstrated in other haematological malignancies, particularly chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and myeloma, with the identification of probable immunological targets such as minor histocompatibility antigens \[[@R6]\], tumor specific antigens \[[@R7]\] and cancer-testis antigens (CTAs) \[[@R8]\].

A number of therapies have been, and are being, developed to target CD19, CD20, CD22 and/or CD52 on adult B-ALL patient blasts (recently reviewed in \[[@R9]\]). One of the most promising antibody therapies is blinatumab, which at the end of phase III clinical trials was shown to increase survival by months in patients with relapsed or refractory disease \[[@R10]\]. In addition, anti-CD19 chimeric antigen receptor-modified T cells (CAR-T-19) therapies have been shown to be able to induce complete remissions \[[@R11]\]. Such studies demonstrate the potential for immunotherapy to treat patients with B-ALL, with novel antigens providing additional targets that can be used to stimulate immune-mediate escape variant destruction.

Our own previous studies of adult B-ALL CD8+ T cells and their recognition of known leukemia antigens/epitopes therein \[[@R12]\] did not identify the same frequency/presence of antigen-specific T-cell populations as myeloid leukemia patients at disease diagnosis. The large numbers of affected lymphoblasts in the bone marrow of patients with adult B-ALL patients may lead to a lack of immune competent B and T cells in the periphery and may explain the general lack of tumor antigens identified to date. We examined the expression of a panel of cancer antigens in adult B-ALL to determine whether any would be promising targets for the immunotherapy of this difficult to treat disease.

RESULTS {#s2}
=======

Reverse transcription-polymerase chain reaction (RT-PCR) analysis of cell lines, patient samples and healthy donors {#s2_1}
-------------------------------------------------------------------------------------------------------------------

We examined the expression of twelve antigens (BCP-20, G250, HAGE, END, NY-ESO-1, PASD1, p68 RNA helicase, SSX2, SSX2IP, survivin, tyrosinase and WT1), identified as promising through a review of the literature, in human cancer cell lines to demonstrate consistency with previously published data and to optimise our assays ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). These results provided positive and negative controls for the expression of each antigen (Table [2A](#T2A){ref-type="table"}). We then examined the expression of the same twelve antigens in thirteen samples from eleven adult B-ALL patients (including twelve samples taken from patients prior to the start of any treatment) and eight healthy volunteers (Table [1](#T1A){ref-type="table"}). No suitable sample was available from ALL003 for RT-PCR analysis. RT-PCR analysis showed that two antigens were expressed in B-ALL patient samples (Table [2B](#T2B){ref-type="table"}) but not healthy donor samples. These were survivin (7/11 B-ALL patients) and *WT1* (6/11 B-ALL patients) with no detectable antigen expression in eight healthy volunteer samples (Figure [1](#F1){ref-type="fig"}; Table [2B](#T2B){ref-type="table"}). All other genes studied (BCP-20, END, G250, HAGE, NY-ESO-1, p68 RNA helicase, SSX2IP and tyrosinase) were detectable in patient samples and healthy volunteers, except PAS domain-containing protein 1 (PASD1) and SSX2 which were not detected in either. Due to limited sample availability we choose six of the antigens, that were differentially expressed in patients compared with normal controls (Survivin, WT1 and END) or of particular interest to our group (PASD1, SSX2, SSX2IP), for further investigation by qPCR.

###### Patient information

  ID       Disease stage   Age (at sampling)   Sex
  -------- --------------- ------------------- --------
  ALL001   Pre-treatment   NK                  NK
  ALL002   Follow-up       19                  Male
  ALL003   Pre-treatment   24                  Male
  ALL004   Diagnosis       22                  Male
  ALL005   Diagnosis       64                  Male
  ALL006   Pre-treatment   19                  Male
  ALL007   Diagnosis       19                  Male
  ALL008   Pre-treatment   19                  Female
  ALL009   Diagnosis       49                  Male
  ALL010   Diagnosis       19                  Male
  ALL011   Pre-treatment   18                  Male
  ALL012   Diagnosis       52                  Female
  ALL013   Pre-treatment   52                  Male

NK, not known.

###### Healthy control (all PB)

  ID      Age   Sex
  ------- ----- --------
  HV003   19    Male
  HV004   NK    NK
  HV006   26    Female
  HV007   19    Male
  HV008   40    Female
  HV016   26    Male
  HV021   NK    Male
  HV032   NK    NK
  HV033   NK    NK

NK, not known.

###### RT-PCR expression of the ten leukemia antigens of interest in (a) human cancer cell lines (b) adult B-ALL patient samples and healthy volunteers

  Antigens/ Cell lines   β-actin     GAPDH       BCP-20     G250       HAGE       END         NY-ESO-1   PASD1      P68 RNA helicase   SSX2       SSX2IP     SURVIVIN   Tyrosinase   WT1
  ---------------------- ----------- ----------- ---------- ---------- ---------- ----------- ---------- ---------- ------------------ ---------- ---------- ---------- ------------ ----------
  **697**                \+          \+          --         --         --         \+          --         --         --                 --         --         --         --           --
  **ARH77**              \+          \+          \+         --         --         \+          --         --         --                 --         \+         --         --           --
  **HeLa**               \+          \+          \+         --         --         \+          --         \+         --                 --         \+         --         --           \+
  **H1299**              \+          \+          \+         --         \+         \+          \+         \+         --                 --         \+         --         --           \+
  **Jurkats**            \+          \+          --         --         \+         \+          --         --         --                 --         --         \+         --           --
  **K562**               \+          \+          \+         \+         \+         \+          --         \+         \+                 \+         \+         \+         --           \+
  **KG1**                \+          \+          --         --         --         \+          --         --         --                 --         --         \+         --           --
  **KYO-1**              \+          \+          \+         --         --         \+          --         \+         --                 --         --         --         --           --
  **NB4**                \+          \+          --         --         --         \+          --         \+         --                 --         --         --         --           \+
  **P39**                \+          \+          \+         \+         --         \+          \+         --         \+                 --         \+         \+         --           \+
  **SW480**              \+          \+          --         \+         --         \+          --         --         --                 --         \+         --         --           --
  **U266**               \+          \+          \+         --         --         \+          --         --         --                 --         \+         --         --           \+
  **U937**               \+          \+          --         --         --         \+          --         --         --                 --         --         --         --           --
  **VLB**                \+          \+          \+         \+         --         \+          --         --         \+                 --         \+         \+         --/+         \+
  **Total**              **14/14**   **14/14**   **8/14**   **4/14**   **3/14**   **14/14**   **2/14**   **5/14**   **3/14**           **1/14**   **8/14**   **5/14**   **1/14**     **7/14**

                            Controls^†^   Antigens                                                                                                                                          
  ------------------------- ------------- ----------- ----------- ---------- ----------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **Patient samples**       **ALL001**    \+          \+          \+         \+          --         \+         \+         --         \+         --         --         --         --         \+
  **ALL002**                \+            \+          \+          \+         --          --         --         --         \+         --         \+         \+         --         \+         
  **ALL004**                \+            \+          --          \+         --          --         \+         --         \+         --         \+         --         \+         --         
  **ALL005**                \+            \+          \+          --         --          --         \+         --         \+         --         --/+       \+         --         \+         
  **ALL006**                \+            \+          \+          \+         \+          \+         \+         --         \+         --         \+         \+         --         \+         
  **ALL007**                \+            \+          --          \+         --          --         \+         --         \+         --         \+         --         --         \+         
  **ALL008**                \+            \+          --          \+         --          --         --         --         --         --         --         --         --         --         
  **ALL009BM**              \+            \+          --          \+         --          --         \+         --         --         --         --         \+         --         --         
  **ALL010BM**              \+            \+          \+          \+         \+          \+         \+         --         \+         --         \+         \+         \+         --         
  **ALL010PB**              \+            \+          \+          \+         --          --         \+         --         \+         --         \+         \+         --         --         
  **ALL012BM**              \+            \+          \+          \+         --                     \+         --         \+         --         \+         \+         \+         --         
  **ALL012PB**              \+            \+          --          \+         --          \+         \+         --         \+         --         \+         \+         --         --         
  **ALL013BM**              \+            \+          --          \+         \+          --         \+         --         --         --         \+         \+         --         \+         
                            **Total‡**    **11/11**   **11/11**   **6/11**   **10/11**   **3/11**   **4/11**   **9/11**   **0/11**   **9/11**   **0/11**   **8/11**   **7/11**   **3/11**   **5/11**
  **HV samples (all PB)**   **HV003**     \+          \+          \+         --          --/+       \+         \+         --         \+         --         \+         --         \+         --
  **HV004**                 \+            \+          --          --                     --         --         --         --         --         --         --         --                    
  **HV006**                 \+            \+          --          --         \+          --         \+         --         \+         --         \+         --         --         --         
  **HV007**                 \+            \+          --          --         --          --         --         --         --         --         --         --         --         --         
                            **HV016**     \+          \+          --         --          --         --         --         --         --         --         --         --         --         --
                            **HV021**     \+          \+          \+         --          --+        \+         \+         --         \+         --         \+         --         \+         --
                            **HV032**     \+          \+          --         --          --         --         --         --         --         --         --         --         --         --
                            **HV033**     \+          \+          --         --          --         --         --         --         --         --         --         --         --         --
                            **Total**     **8/8**     **8/8**     **2/8**    **0/8**     **3/8**    **2/8**    **3/8**    **0/8**    **3/8**    **0/8**    **3/8**    **0/8**    **3/8**    **0/8**

BM: bone marrow; HV: healthy volunteer; PB: peripheral blood. ^†^: controls for the integrity of the cDNA samples for PCR amplification; ^‡^number of patients with antigen positive samples (*n* = 11) encompassing the analysis of 13 samples.

![Expression of transcripts encoding leukemia antigens in cell lines, primary adult B-ALL patients and normal donors\
β-actin was used as a positive control for the ability of primers to amplify the cDNA. N was a no (cDNA) template control. Right hand side labels indicate expected product size and M indicates the location of the 1kB marker (HyperLadder I). RT-PCR data is representative of at least two independent experiments.](oncotarget-09-3853-g001){#F1}

qPCR analysis of antigen expression in B-ALL and healthy donor samples {#s2_2}
----------------------------------------------------------------------

A two-way ANOVA test was used to determine whether there was a statistical difference between transcript expression of END, PASD1, SSX2, SSX2IP, Survivin and WT1, as determined by qPCR, in B-ALL patients (ALL001-8, 11 and 14) compared with healthy volunteers. Survivin had a significantly higher expression in seven of the ten B-ALL patients analysed, compared to healthy controls (*p* = 0.015) (Figure [2A](#F2){ref-type="fig"}). Its median ΔC~T~ value (7.19) in patients was much lower compared to the median ΔC~T~ value (12.81) in normal controls. *WT1* was expressed by three out of ten adult B-ALL patients (Figure [2B](#F2){ref-type="fig"}) however the median ΔC~T~ of B-ALL patients and normal controls, 12.88 and 12.81 respectively, were almost equal. Therefore, there was no significant difference detected by the two-way ANOVA test between these two groups.

![Relative expression of transcripts encoding each antigen in the B-ALL patients compared to the healthy volunteers\
Dots indicate the ΔC~T~ values, whereby the C~T~ of the endogenous control *GAPDH* is subtracted from the C~T~ of each gene. Genes that were not expressed were assigned a C~T~ value of 40. The higher the ΔC~T~ value, the less antigen was expressed. All ΔC~T~ values for antigens were lower level than the reference gene *GAPDH*. Streaked dots, representing patient sample ALL004, were outliers that do not represent antigen expression. *P*-values were determined using a two-way ANOVA test. Ns, not significant.](oncotarget-09-3853-g002){#F2}

Expression of *PASD1* and synovial sarcoma, X breakpoint 2 (*SSX2)* expression were not detected in any of the adult B-ALL patients or healthy volunteers (Figures [2C](#F2){ref-type="fig"} and [2D](#F2){ref-type="fig"}). Nine out of ten patients expressed *SSX2IP* (Figure [2E](#F2){ref-type="fig"}) while seven out of ten expressed END (Figure [2F](#F2){ref-type="fig"}). Although the expression of these genes were high, their transcripts were also found in three of five healthy volunteers.

Immunolabelling of antigen expression in B-ALL using immunocytochemistry {#s2_3}
------------------------------------------------------------------------

The cell lines K562, OCI-LY3 and MDA-MB-231 were used to demonstrate the effectiveness of immunolabelling to detect the expression of END, PASD1, SSX2, SSX2IP, survivin, and WT1 (Table [3](#T3){ref-type="table"}). Four out of five antigens had a cytoplasmic and nuclear localisation, while WT1 was only found in the cytoplasm of the K562 cells (Figure [3](#F3){ref-type="fig"}). The immunoreactivity score of both survivin and WT1 was moderate, while SSX2 and SSX2IP showed a weak labelling in K562 (Table [3](#T3){ref-type="table"}). END was not expressed in the K562 cell line. OCI-LY-3 cell line was used as an extra control for the expression of PASD1 and showed high levels of PASD1 in the cytoplasm and near the cell membrane. END was moderately expressed on the surface of MDA-MB-231 cells grown on coverslips, confirming the findings of previous studies \[[@R13]\].

###### Frequency of immunolabelling of the six antigens of interest in K562, OCI-LY-3 and MDA-MB-23 cells.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Staining intensity   Stained cells per microscopic image (%)   Immunoreactivity\   Subcellular localisation                                                                                                                                           
                                                                 score                                                                                                                                                                                  
  -------------------- ----------------------------------------- ------------------- -------------------------- --------------- --------------- ------------- --------------- --------------- --------------- -------------------- -------------------- --------------------
                       K562                                      OCI-LY-3            MDA-MB-231                 K562            OCI-LY-3        MDA-MB-231    K562            OCI-LY-3        MDA-MB-231      K562                 OCI-LY-3             MDA-MB-231

  Actin                4                                         4                   4                          185/203 (91)    563/569 (99)    53/53 (100)   364\            396\            400\            Cytoplasm, nucleus   Cytoplasm, nucleus   Cytoplasm, nucleus
                                                                                                                                                              (Very high)     (Very high)     (Very high)                                               

  END                  0                                         ND                  3                          0 (0)           ND              5/45\         0\              ND              33 (Moderate)   ND                   ND                   Surface
                                                                                                                                                (11.1)        (Negative)                                                                                

  PASD1                2                                         3                   ND                         18/261 (6.9)    181/292 (62)    ND            14\             186\            ND              Cytoplasm, nucleus   Surface, cytoplasm   ND
                                                                                                                                                              (Weak)          (High)                                                                    

  SSX2                 2                                         0                   ND                         23/255 (9)      0\              ND            18\             0\              ND              Cytoplasm, nucleus   \-                   ND
                                                                                                                                (0)                           (Weak)          (Negative)                                                                

  SSX2IP               2                                         1                   ND                         17/195 (8.7)    45/241 (18.7)   ND            17\             19\             ND              Cytoplasm, nucleus   Surface              ND
                                                                                                                                                              (Weak)          (Weak)                                                                    

  Survivin             2.5                                       2.5                 ND                         71/190 (37.4)   67/364 (18.4)   ND            94 (Moderate)   46 (Moderate)   ND              Cytoplasm, nucleus   Cytoplasm, nucleus   ND

  WT1                  2.5                                       1                   ND                         36/236 (15.3)   50/352 (14.2)   ND            38 (Moderate)   14\             ND              Cytoplasm            Cytoplasm            ND
                                                                                                                                                                              (Weak)                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Actin acted as positive control. Negative controls were cells only, two isotype and no primary antibody controls. Data was representative of two independent experiments. ND, not done.

![Immunolabelling of the key antigens of interest in two primary adult B-ALL patient samples\
Brown precipitate indicates the immunlabelling of test protein in the cell. Actin acted as the positive control for the assay. Two isotype control antibodies (Ms and Rb isotype) were used as negative controls to ensure there was minimal non-specific antibody binding to antigen. All pictures were taken at 400X magnification and were representative of at least two independent experiments.](oncotarget-09-3853-g003){#F3}

Actin was used as a positive control for ICC immunolabelling and, as expected, all patients and healthy volunteers had a moderate (30--143) to high immunoreactivity score (144--228) (Table [4](#T4){ref-type="table"}). Two isotype matched control antibodies ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) or no primary antibody controls were used as negative controls to determine whether there was any non-specific staining. All patient samples (*n* = 10) expressed moderate to high levels of each antigen (SSX2, SSX2IP, Survivin and WT-1) while survivin expression was not detected in the healthy volunteer samples. In contrast, one of six healthy volunteers expressed SSX2 at High levels, two of six healthy volunteers had detectable SSX2IP expression detectable at moderate levels, and WT1 at moderate levels. The ICC experiments were performed twice, with controls, due to limited samples being available, but the results were reproducible.

###### Immunoreactivity score for the antigens SSX2, survivin, SSX2IP and WT1 as detected by ICC in B-ALL patient samples and healthy donors

  Patient number   Cells only   Controls\#   Isotype Rabbit   Actin   SSX2           SSX2IP       Survivin     WT1
  ---------------- ------------ ------------ ---------------- ------- -------------- ------------ ------------ ------------
  ALL001           0            0            0                96      83.5 (mod)     89.5 (mod)   82.5 (mod)   94.5 (mod)
  ALL002           0            0            0                300     196 (high)     99.5 (mod)   89.5 (mod)   200 (high)
  ALL003           0            0            0                98.5    187 (high)     200 (high)   98 (mod)     92.5 (mod)
  ALL004           0            0            0                94.5    91 (mod)       96 (mod)     95.5 (mod)   84.5 (mod)
  ALL005           0            0            0                198     188 (high)     178 (high)   93.5 (mod)   95.5 (mod)
  ALL006           0            \-           0                200     200 (high)     198 (high)   95.5 (mod)   96 (mod)
  ALL007           0            0            0                200     198 (high)     200 (high)   186 (high)   96 (mod)
  ALL008           0            0            0                200     84 (mod)       91 (mod)     89.5 (mod)   79 (mod)
  ALL009 (BM)      0            0            0                197     188 (high)     176 (high)   195 (high)   181 (high)
  ALL009 (PB)      0            0            0                200     171 (high)     90.5 (mod)   175 (high)   196 (high)
  ALL010 (BM)      0            0            0                99      93 (mod)       95 (mod)     89 (mod)     99 (mod)
  ALL010 (PB)      0            0            0                97.5    181 (high)     200 (high)   100 (mod)    100 (mod)
  Total            0/10         0/10         0/10             10/10   10/10          10/10        10/10        10/10
  HV003            0            0            0                273     0              0            0            35.5 (mod)
  HV004            0            0            0                198     151.5 (high)   38 (mod)     0            0
  HV007            0            0            0                267     0              0            0            0
  HV008            0            0            0                187     0              0            0            0
  HV016            0            0            0                288     0              0            0            64.5 (mod)
  HV021            0            0            0                189     0              0            0            0
  Total            0/6          0/6          0/6              6/6     1/6            1/6          0/6          2/6

Actin acted as a positive control. ^**\#**^The two isotype antibodies were used as negative controls or one isotype control and one test with no primary antibody. Immunoreactivity scores are as follows:- 0 = negative; 1--29:weak; 30--143: moderate (mod) and 144--228: high; \>228: very high. Data is representative of at least two independent experiments.

Gene expression analysis {#s2_4}
------------------------

Bioinformatic analysis of the publically available gene expression data set GSE38403 \[[@R14]\], indicated that survivin (*p* = 0.013) was significantly over-expressed in the B-ALL patient cohort (*n* = 215) compared to healthy B-cell controls (*n* = 12). Furthermore, of the twelve candidate genes investigated only p68 DNA helicase, SSX2IP, Survivin and WT1 showed significant differences in expression when compared across individual cytogenetic groups (Table [5](#T5){ref-type="table"}). Elevated END or survivin expression was significantly associated with the t(9;21) translocation while p68 DNA helicase, SSX2IP, Survivin and WT1 expression were associated with different 11q23 /MLL abnormalities. We did examine whether there was a correlation between OS and event free survival (EFS) with the expression of each gene but none achieved significance and the closest to achieving significance was SSX2 interacting protein (SSX2IP) with an association with OS with a *p* value of 0.078.

###### Microarray analysis indicating the significance of the association between the expression of each antigen and sample type, ALL compared with healthy pre B-cells and the presence or absence of cytogenetics abnormalities

                     *p*-value                                                          
  ------------------ ----------- ------- ---------- ------- ---------- ------- -------- -------
  SSX2IP             NS          NS      0.0038     NS      0.032      0.018   0.043    NS
  P68 RNA Helicase   NS          NS      0.0256     NS      NS         0.003   NS       NS
  WT1                NS          NS      4.23E-11   NS      4.65E-06   0.026   0.0005   0.01
  SURVIVIN           0.015       0.015   0.0035     0.003   NS         0.024   NS       0.023

Only those antigens that had a significant association between their expression and the clinical features analysed are shown.

NA: no abnormality; NS: not significant †: single cytogenetic abnormalities.

^\*\*^ - highly significant.

^\*\*\*^ - very highly significant.

DISCUSSION {#s3}
==========

Most patients with adult B-ALL achieve first remission with conventional treatment however many relapse with high associated mortality. There is an acute need for therapies that can remove minimal residual disease and delay, if not prevent, relapse for these patients. To this end, we have investigated twelve known leukemia antigens for their expression in adult B-ALL.

Survivin and WT1 were the only antigens detected in patients but not healthy volunteers by RT-PCR and ICC, but only survivin had a statistically significant elevation in expression between the adult B-ALL cohort and healthy volunteer group by qPCR. This adds to a growing body of studies that have shown an association between survivin expression and ALL. Survivin is upregulated in a large number of solid tumors and haematological malignancies, including AML and ALL \[[@R15]\]. It acts as a dual regulator of both apoptosis and cell cycle progression, and is a member of the inhibitors of apoptosis proteins (IAP) family. Survivin plays a role in the cells' escape from apoptotic pathways and is considered an important mechanism that facilitates leukaemogenesis and the resistance of tumors to chemotherapy. Survivin overexpression has been shown to initiate haematologic malignancies in transgenic mice \[[@R16]\] while its synthesis and degradation is controlled in a cell cycle-dependent course, with increasing transcription during G~1~ that peaks in G~2~-M. This supports its role in the regulation of the mitotic spindle checkpoint \[[@R17]\]. A study by Esh and colleagues showed that the knockdown of survivin mRNA via short-hairpin RNA or a locked antisense oligonucleotide reduced its gene expression, increased apoptosis in leukemia cell lines and accumulated the cells in the sub-G1 phase of the cell cycle \[[@R18]\]. In addition, silencing of the survivin gene in an ALL xenograft animal model improved chemotherapeutic responses while overexpression of the survivin gene has been associated with poor prognosis in paediatric ALL patients \[[@R18]\]. Mori and colleagues examined survivin expression in ALL patients using RT-PCR and found survivin expression in 11 of 16 ALL patients, but not in normal bone marrow (BM) cells \[[@R19]\]. Yang *et al.* also identified an elevation in vascular endothelial growth factor (*VEGF*) levels that coincided with survivin levels in 40 ALL patients by RT-PCR and western blotting \[[@R20]\].

Due to its limited expression in normal non-foetal tissues, survivin is a highly attractive immunotherapeutic target. When analysing five HLA-A2 positive adult ALL patient samples on a pMHC array \[[@R12]\] we did not detect any survivin-specific T cells that had bound to either of the HLA-A2 restricted survivin epitopes examined (survivin 5--11 or 96--104; \[[@R21]\]) even at a detection sensitivity of at least 0.02% of the CD8+ population. However other groups have found that survivin-specific T cell responses can be expanded in a number of pre-clinical and clinical settings, most recently a Phase II multi-epitope vaccine of five survivin peptides with adjuvant that resulted in the expansion of survivin-specific T cell responses in patients with solid cancers \[[@R22]\]. Although survivin was listed as one of the top 15 prioritised antigens by virtue of its therapeutic function, immunogenicity, specificity and oncogenicity among other features \[[@R23]\], it has been shown to be downregulated in both chronic myeloid leukemia (CML) \[[@R24]\] and AML-derived leukaemic stem cells (LSCs) \[[@R25]\]. Although this negatively impacts the value of survivin for the immunotherapy of myeloid leukemia, it's epitopes have been characterised for immunotherapy (recently reviewed in \[[@R26]\]) and are likely to be useful in the generation of anti-tumor responses that may lead to epitope spreading and, at the least, could elongate the remission period and enable the administration of LSC-targeting treatments.

Our previous serological analysis of recombinant tumor cDNA expression libraries (SEREX) analysis of AML patient sera, identified *SSX2IP* and *PASD1*, as well as SSX2IP's interacting partner, SSX2, as potential targets for the immunotherapy of myeloid leukemia \[[@R27]\]. Both PASD1 and SSX2 are CTAs that are expressed in cancer cells and immunologically protected sites. This restricted expression makes CTAs attractive targets for immunotherapy as their targeting should not lead to catastrophic auto-immune responses against healthy tissue. However, *PASD1* and *SSX2* transcripts were not detected in any of the adult B-ALL patients or healthy controls, although all of the adult B-ALL patient samples examined showed positive immunolabelling for SSX2 at moderate to high levels. This indicates that SSX2 protein expression may be worthy of further investigation in B-ALL patient samples, and our results suggest a lack of correlation between detectable *SSX2* transcription and the presence of SSX2 protein.

In contrast to our own previous studies \[[@R27]\], *SSX2IP* transcripts were found in patient samples and healthy control PB by RT-PCR, and qPCR, suggesting an improved sensitivity in our detection of *SSX2IP* transcripts in the last decade, as the RT-PCR primers and reagents remained unchanged. Surprisingly NY-ESO-1 transcripts were also found in B-ALL patient samples and normal donor PB samples by RT-PCR. Both findings require further investigation but may reflect the rapid proliferation and enhanced turnover of the white blood cells compared with many other healthy cell types or a technical error on our part, although we used multiple controls to ensure we did not have any contaminating gDNA in our cDNA samples. In addition we used previously published primers with our own validated techniques. BCR/ABL, a hallmark of CML has also been found in 10--30% of tested healthy adults increasing in prevalence with donor age \[[@R28]\]. The Philadelphia chromosome translocation product has been shown to be essential for the development of CML yet remains present in healthy donors without doing so, suggesting an, as yet undefined, requirement for additional events to achieve full transformation to the malignant phenotype. Ismail *et al.* \[[@R29]\] suggested this occurrence was due to an accumulation of DNA damage with age and it may be a feature of the rapidly proliferating, high turnover "normal" white blood cells.

Another of the potential immunotherapeutic targets for B-ALL that we investigated was the LAA WT1. Inoue *et al.* demonstrated consistently increased *WT1* expression levels in most myeloid and lymphoid acute leukemias via RT-PCR \[[@R30]\]. These results were confirmed by Cilloni *et al*, who detected WT1 overexpression in all 48 ALL samples at diagnosis (BM and PB) when using qPCR \[[@R31]\]. They showed that *WT1* expression was detectable, but that *WT1* transcript levels in normal BM and PB were extremely low and often below the qPCR detection limit. Therefore, *WT1* is a promising marker to discriminate between normal and leukaemic haematopoiesis, and effective in establishing the presence, persistence and/or reappearance of leukaemic blasts for diagnosis or detection of minimal residual disease (MRD). Our qPCR results demonstrated *WT1* mRNA expression in three out of the ten adult B-ALL patients, but none of the healthy volunteers.

In summary, our study has demonstrated the value of pursuing survivin as a target for the immunotherapy of adult B-ALL, through our demonstration of its transcription and translation as early as disease diagnosis. This is a rare disease with high associated mortality. The fact that most patients can achieve first remission provides a time point during which residual tumor cells may be targeted by immunotherapy. The reduction or, ideally, removal of MRD could provide an opportunity to extend, if not prevent, relapse benefitting patient survival. A number of clinical trials are underway that target survivin including those using immunotherapy protocols or survivin-inhibitors. Our study has identified a patient group who would likely benefit from their application and warrants further investigation.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and patient samples {#s4_1}
------------------------------

Human cancer cell lines were used to measure the expression of the antigens and optimise assays. All were obtained from ATCC (Sigma-Aldrich Co. Ltd) and grown in RPMI 1640 or DMEM media (Sigma-Aldrich Company Ltd., Dorset, U.K.) containing 10% foetal bovine serum (FBS) and 1% penicillin and streptomycin (both Thermo Fisher Scientific, Leicestershire, UK), in a humidified incubator at 37°C with 5% CO~2.~ K562 was positive for the expression of most antigens examined ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) as described previously.

16 samples were collected from 14 adult B-ALL patients at various treatment time points, but predominantly diagnosis and pre-treatment (Table [1A](#T1A){ref-type="table"}), from the Departments of Haematology at University Hospital Southampton NHS FT, Portsmouth Hospitals NHS Trust and the Royal Devon and Exeter Foundation Trust following informed consent and local ethical approval (REC 07/H0606/88). Leukaemic blasts and mononuclear cells were isolated from PB and/or BM in EDTA. White blood cells were also isolated from age and sex-matched normal donor PB following informed consent and local ethical approval (LREC 228/02/T).

Identification of antigens for study in B-ALL {#s4_2}
---------------------------------------------

Due to a lack of known antigens that can act as targets for the immunotherapy of B-ALL, we identified a list of antigens of potential interest for further study. We had previously identified PASD1, SSX2IP and HAGE expression in presentation AML \[[@R27], [@R32]\] and examined presentation acute leukemia patients for T cells that recognized epitopes within G250, NY-ESO-1, tyrosinase, p68 RNA helicase, WT1 and survivin \[[@R12]\]. We examined SSX2 because of its known interaction with SSX2IP \[[@R33]\], BCP-20 based on its expression in solid tumors \[[@R34]\] and END based on its detection in paediatric leukemia and association with patient outcome \[[@R35]\].

RT-PCR analysis of antigen expression in patient and normal donor samples {#s4_3}
-------------------------------------------------------------------------

To evaluate the expression of the most promising antigens in normal and malignant tissues we isolated RNA from BM and PB samples using QIAGEN RNeasy kit (QIAGEN Ltd.). mRNA was DNase I treated (Roche Products Ltd, Herts, U.K.), cleaned using a RNeasy kit (Qiagen), checked on a 1% agarose-TBE gel and quantified using a spectrophotometer. We prepared cDNA using the MBI Fermentas RevertAid First Strand cDNA synthesis kit (MBI Fermentas Ltd, Helena BioSciences Ltd, Sunderland, U.K.), utilising the random hexamer primers.

To test the fidelity of the cDNA samples, each cDNA was subjected to β-actin PCR. All PCR amplifications were performed on 200 ng of cDNA, mRNA (to show no gDNA was present in the mRNA samples) or gDNA (to demonstrate that the amplification of gDNA led to a product of a larger size than cDNA). We used 12.5 µl ReadyMix Taq PCR reaction mix (Sigma) and 1.5 mM MgCl~2~ in a final volume of 25 µl and primers were used as described previously:- *BCP-20* \[[@R36]\], *G250* \[[@R37]\], *HAGE* \[[@R32]\], *NY-ESO-1* \[[@R38]\], *PASD1* \[[@R27]\], p68 RNA helicase \[[@R39]\], SSX2 \[[@R40]\], *SSX2IP* \[[@R27]\], tyrosinase \[[@R41]\] and *WT1* \[[@R42]\]. To detect survivin we used the forward: 5-GATGACGACCCCATAGAGGAAC-3′ and reverse: 5′- GGGTTAATTCTTCAAACTGCTTCT-3′ primers \[[@R43]\]. Two primers were designed using the Primer3 Output MIT educational tool ([www.genome.wi.mit.edu](www.genome.wi.mit.edu)) to flank introns and were assessed for specificity using BLAST web based programmes. These were β-actin forward 5′-CATGGATGATGATATCGCCGC-3′ and reverse 5′-CCATCACGCCCTGGTGC-3′ and END forward 5′-CCCTTCTCTAAGGAAGCGCA-3′ and reverse 5′- AGTTGCTGTCCGAAGGATGG-3′. PCR products were electrophoresed on 1% TBE-agarose gels and assessed following staining with 10 µg/ml ethidium bromide.

Sequencing of PCR products {#s4_4}
--------------------------

After gel electrophoresis of the PCR products and image capture, bands were excised from the agarose gel and placed in 1.5 ml sterile eppendorf tube. These products were extracted from the gel bands using the PCR gel extraction kit (Qiagen). Where available, products from three independent PCR reactions on the same template were sent for Sanger sequencing to the DNA sequencing facility at the University of Cambridge. We analysed each sequence using Finch TV software and BLASTN to compare similarity between the PCR products and their target cDNA sequences.

QPCR analysis {#s4_5}
-------------

QPCR was performed using SYBR Green technology with the QuantiTect Primer Assays and QuantiNova SYBR Green PCR kit (all Qiagen), to investigate the relative expression of six TAAs in ten adult B-ALL samples (ALL001-8, 11 and 14), as well as *GAPDH* as a control for sample loading and the quality of the cDNA. Each primer was tested on at least one human cancer cell line that was known to express the antigen of interest ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}), based on previously published studies. To control for contamination within the qPCR reagents, a no cDNA control was included on every qPCR plate whereby cDNA was replaced by RNase-free H~2~O. In addition, each sample was plated in triplicate on the 96-well qPCR plate (Applied Biosystems, USA) to identify any outliers in the dataset. The reaction volumes were 10 µL 2X QuantiNova SYBR green PCR MM, 0.1 µL ROX reference dye, 2 µL primer assay and 6.9 µL RNase-free H~2~O, making a total volume of 19 µL added to each well in the 96-well plate.

The thermocycler (StepOne Plus Real-Time PCR system, Applied Biosystems) ran a heating step for 2 minutes at 95°C, then 40 cycles were run, whereby each cycle was set to denature for 5 s at 95°C, and to anneal plus extend primers in a combined step for 10 s at 60°C. This was immediately followed by a melt curve stage of 15 s at 95°C, 1 min at 60°C and 15 s at 95°C, to verify the specificity of the amplification, e.g. no non-specific primer dimer formation. Data was compared using StepOne software v2.0 (Applied Biosystems) and the comparative C~T~ method \[[@R44]\]. When comparing antigen expression in B-ALL to healthy controls, the results were normalised with the *GAPDH* reference gene (ΔC~T~ = C~T~ antigen--C~T~ GAPDH). All qPCR data were analysed with a two-way ANOVA test for pairwise comparisons, using Partek Genomic Software (Partek Inc., USA).

Immunocytochemistry {#s4_6}
-------------------

Leukocytes were isolated following a 30min incubation of PB and/or BM samples with red cell lysis buffer (155 mM NH~4~Cl, 10 mM KHCO~3~, 0.1 mM EDTA), after which leukocytes were pelleted by centrifugation for 10 min at 800 g. Leukocytes or cells from lines were resuspended in PBS at 5 × 10^6^/ml, with 10 ul cells spotted at each of two sites on microscope glass slides. Slides were double wrapped in saran wrap and stored at --20^o^C until required for use. Immunocytochemistry was performed as described previously \[[@R45]\] using antibodies as detailed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Due to the cellular localisation of END on the cell surface, the MDA-MB-231 cell line was grown to 50--70% confluence on glass coverslips. Then, the culture medium from each well was aspirated and cover slips were rinsed in PBS. The coverslips were air dried for 4--6 h, wrapped in saran wrap and stored in --20°C freezer. Actin was used as a positive control for the successful performance of ICC while isotype, no primary and no secondary antibody immunolabelling acted as negative controls, used to detect non-specific staining. Lillies-Mayer Haematoxylin was used as a countertstain.

Staining intensities were scored according to a five-tiered scale described originally by \[[@R46]\] as follows:- 0: no staining; 1: background; 2: weak staining; 3: moderate staining; 4: strong staining. The percentage of positively stained cells was based on the cell count of stained cells per microscopic view, and represented on a five-tiered scale (0: 0%; 1: 1--10%; 2: 11--50%; 3: 51--80%; 4: \> 80%). The final immunoreactivity score was obtained by multiplication of the percentage of positive stained cells per microscopic view by the value for staining intensity (0 = negative, 1--29 = weak, 30--143 = moderate, 144--228 = high and \> 228 = very high staining) \[[@R47]\].

Gene expression analysis {#s4_7}
------------------------

To determine the relative expression of the antigens of interest in a larger cohort of adult B-ALL samples and healthy controls, we performed metadata analysis on a publically available microarray expression data (GSE38403) \[[@R14]\] which utilised 215 adult B-cell ALL and 12 normal pre-B samples. The CEL files were downloaded and imported in the Partek Genomic Suite, normalised using RMA, and subjected to ANOVA analysis which was filtered on significance for the generation of the gene lists.

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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AML

:   acute myeloid leukemia

B-ALL

:   B-cell acute lymphocytic leukemia

BM

:   bone marrow

CML

:   chronic myeloid leukemia

CTA

:   cancer-testis antigens

GvL

:   graft versus leukemia

LAA

:   leukemia associated antigens

LSC

:   leukaemic stem cells

MRD

:   minimal residual disease

OS

:   overall survival

PASD1

:   PAS domain-containing protein 1

PB

:   peripheral blood

RT-PCR

:   reverse transcription -- polymerase chain reaction

RQ

:   real-time quantitative

SSX2

:   synovial sarcoma, X breakpoint 2

SSX2IP

:   SSX2 interacting partner

WT1

:   Wilms tumor-1
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